If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...
DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to ...
Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...
It has had strong momentum since November, but there is still plenty of upside left.
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Investor's Business Daily on MSN
Could 2026 be Dexcom's 'get right' year? New CEO Jake Leach says yes.
For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is ...
DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full ...
Zacks Investment Research on MSN
Here's why DexCom (DXCM) is a strong momentum stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...
The average one-year price target for DexCom (XTRA:DC4) has been revised to 77,50 € / share. This is a decrease of 12.36% from the prior estimate of 88,43 € dated November 9, 2025. The price target is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results